Cargando…

Circulating CD36 Is Reduced in HNF1A-MODY Carriers

INTRODUCTION: Premature atherosclerosis is a significant cause of morbidity and mortality in type 2 diabetes mellitus. Maturity onset diabetes of the young (MODY) accounts for approximately 2% of all diabetes, with mutations in the transcription factor; hepatocyte nuclear factor 1 alpha (HNF1A) acco...

Descripción completa

Detalles Bibliográficos
Autores principales: Bacon, Siobhan, Kyithar, Ma P., Schmid, Jasmin, Costa Pozza, Andre, Handberg, Aase, Byrne, Maria M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771933/
https://www.ncbi.nlm.nih.gov/pubmed/24069322
http://dx.doi.org/10.1371/journal.pone.0074577
_version_ 1782284247893016576
author Bacon, Siobhan
Kyithar, Ma P.
Schmid, Jasmin
Costa Pozza, Andre
Handberg, Aase
Byrne, Maria M.
author_facet Bacon, Siobhan
Kyithar, Ma P.
Schmid, Jasmin
Costa Pozza, Andre
Handberg, Aase
Byrne, Maria M.
author_sort Bacon, Siobhan
collection PubMed
description INTRODUCTION: Premature atherosclerosis is a significant cause of morbidity and mortality in type 2 diabetes mellitus. Maturity onset diabetes of the young (MODY) accounts for approximately 2% of all diabetes, with mutations in the transcription factor; hepatocyte nuclear factor 1 alpha (HNF1A) accounting for the majority of MODY cases. There is somewhat limited data available on the prevalence of macrovascular disease in HNF1A-MODY carriers with diabetes. Marked insulin resistance and the associated dyslipidaemia are not clinical features of HNF1A-MODY carriers. The scavenger protein CD36 has been shown to play a substantial role in the pathogenesis of atherosclerosis, largely through its interaction with oxidised LDL. Higher levels of monocyte CD36 and plasma CD36(sCD36) are seen to cluster with insulin resistance and diabetes. The aim of this study was to determine levels of sCD36 in participants with HNF1A-MODY diabetes and to compare them with unaffected normoglycaemic family members and participants with type 2 diabetes mellitus. METHODS: We recruited 37 participants with HNF1A-MODY diabetes and compared levels of sCD36 with BMI-matched participants with type 2 diabetes mellitus and normoglycaemic HNF1A-MODY negative family controls. Levels of sCD36 were correlated with phenotypic and biochemical parameters. RESULTS: HNF1A-MODY participants were lean, normotensive, with higher HDL and lower triglyceride levels when compared to controls and participants with type 2 diabetes mellitus. sCD36 was also significantly lower in HNF1A-MODY participants when compared to both the normoglycaemic family controls and to lean participants with type 2 diabetes mellitus. CONCLUSION: In conclusion, sCD36 is significantly lower in lean participants with HNF1A-MODY diabetes when compared to weight-matched normoglycaemic familial HNF1A-MODY negative controls and to lean participants with type 2 diabetes mellitus. Lower levels of this pro-atherogenic marker may result from the higher HDL component in the lipid profile of HNF1A-MODY participants.
format Online
Article
Text
id pubmed-3771933
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37719332013-09-25 Circulating CD36 Is Reduced in HNF1A-MODY Carriers Bacon, Siobhan Kyithar, Ma P. Schmid, Jasmin Costa Pozza, Andre Handberg, Aase Byrne, Maria M. PLoS One Research Article INTRODUCTION: Premature atherosclerosis is a significant cause of morbidity and mortality in type 2 diabetes mellitus. Maturity onset diabetes of the young (MODY) accounts for approximately 2% of all diabetes, with mutations in the transcription factor; hepatocyte nuclear factor 1 alpha (HNF1A) accounting for the majority of MODY cases. There is somewhat limited data available on the prevalence of macrovascular disease in HNF1A-MODY carriers with diabetes. Marked insulin resistance and the associated dyslipidaemia are not clinical features of HNF1A-MODY carriers. The scavenger protein CD36 has been shown to play a substantial role in the pathogenesis of atherosclerosis, largely through its interaction with oxidised LDL. Higher levels of monocyte CD36 and plasma CD36(sCD36) are seen to cluster with insulin resistance and diabetes. The aim of this study was to determine levels of sCD36 in participants with HNF1A-MODY diabetes and to compare them with unaffected normoglycaemic family members and participants with type 2 diabetes mellitus. METHODS: We recruited 37 participants with HNF1A-MODY diabetes and compared levels of sCD36 with BMI-matched participants with type 2 diabetes mellitus and normoglycaemic HNF1A-MODY negative family controls. Levels of sCD36 were correlated with phenotypic and biochemical parameters. RESULTS: HNF1A-MODY participants were lean, normotensive, with higher HDL and lower triglyceride levels when compared to controls and participants with type 2 diabetes mellitus. sCD36 was also significantly lower in HNF1A-MODY participants when compared to both the normoglycaemic family controls and to lean participants with type 2 diabetes mellitus. CONCLUSION: In conclusion, sCD36 is significantly lower in lean participants with HNF1A-MODY diabetes when compared to weight-matched normoglycaemic familial HNF1A-MODY negative controls and to lean participants with type 2 diabetes mellitus. Lower levels of this pro-atherogenic marker may result from the higher HDL component in the lipid profile of HNF1A-MODY participants. Public Library of Science 2013-09-12 /pmc/articles/PMC3771933/ /pubmed/24069322 http://dx.doi.org/10.1371/journal.pone.0074577 Text en © 2013 Bacon et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bacon, Siobhan
Kyithar, Ma P.
Schmid, Jasmin
Costa Pozza, Andre
Handberg, Aase
Byrne, Maria M.
Circulating CD36 Is Reduced in HNF1A-MODY Carriers
title Circulating CD36 Is Reduced in HNF1A-MODY Carriers
title_full Circulating CD36 Is Reduced in HNF1A-MODY Carriers
title_fullStr Circulating CD36 Is Reduced in HNF1A-MODY Carriers
title_full_unstemmed Circulating CD36 Is Reduced in HNF1A-MODY Carriers
title_short Circulating CD36 Is Reduced in HNF1A-MODY Carriers
title_sort circulating cd36 is reduced in hnf1a-mody carriers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771933/
https://www.ncbi.nlm.nih.gov/pubmed/24069322
http://dx.doi.org/10.1371/journal.pone.0074577
work_keys_str_mv AT baconsiobhan circulatingcd36isreducedinhnf1amodycarriers
AT kyitharmap circulatingcd36isreducedinhnf1amodycarriers
AT schmidjasmin circulatingcd36isreducedinhnf1amodycarriers
AT costapozzaandre circulatingcd36isreducedinhnf1amodycarriers
AT handbergaase circulatingcd36isreducedinhnf1amodycarriers
AT byrnemariam circulatingcd36isreducedinhnf1amodycarriers